FDA Approves Breakthrough Drug Rasonque for Metastatic Pancreatic Cancer

The FDA approved Rasonque (daraxonrasib), a groundbreaking new drug to treat metastatic pancreatic cancer. Photo courtesy of Revolution Medicines The FDA approved Rasonque, a new drug to treat the most common type of pancreatic cancer. A clinical trial found that those who received Rasonque had more than double the average survival rate: around 13 months compared to just over 6 months with chemotherapy alone. Pancreatic cancer was the sixth most common cause of cancer-related death globally in 2024. A groundbreaking new drug has ushered in a new era of treatment for a deadly form of prostate cancer. The Food and Drug Administration (FDA) approved a new drug, Rasonque (daraxonrasib), on August 26, to treat pancreatic adenocarcinoma, the most common type of pancreatic cancer. Pancreatic cancer was ranked the 12th most common cancer in 2024, with more than 530,000 estimated diagnoses globally. It is the sixth most common cause of cancer-related death, contributing to more than 490,000 deaths. The new drug targets a specific protein known to drive pancreatic cancer tumor growth. The medication is for people with metastatic pancreatic adenocarcinoma — meaning the cancer has moved outsi…

≈